Form D · Other
NERVGEN PHARMA CORP.
Vancouver, A1 · CIK 0001751912
Offering snapshot reported Dec 14, 2021 · SEC filing
- Reported sold
- $652K Offering amount: $1.05M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 29, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 14, 2021 | Initial | $651,815 | No comparison | 17 | SEC filing |
| Aug 25, 2021 | Amendment | $2,194,379 | No comparison | Not reported | SEC filing |
| Aug 17, 2021 | Initial | $263,692 | No comparison | 3 | SEC filing |
| Jun 2, 2021 | Amendment | $285,141 | $0vs Jun 3, 2020 | 13 | SEC filing |
| Aug 25, 2020 | Initial | $2,194,379 | No comparison | 16 | SEC filing |
| Jun 3, 2020 | Initial | $285,141 | No comparison | 13 | SEC filing |
| Nov 22, 2019 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Mar 21, 2019 | Initial | $1,196,500 | No comparison | 28 | SEC filing |
| Sep 20, 2018 | Initial | $111,418 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-424846
Total amount remaining to be sold represents the maximum potential exercise price of warrants. Subscriptions paid in Canadian currency converted to US dollars at CAD$1.2621= USD$1.00.
Units consist of one common share and one-half common share purchase warrant, each whole warrant exercisable at CAD$3.20 per share until November 29, 2023.
Source: Form D, filed Dec 14, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Abrams | Director |
| William Adams | Executive |
| Brian Bayley | Director |
| Denis Bosc | Executive |
| Paul Brennan | Director, Executive |
| Amy Franke | Executive |
| Glenn Ives | Director |
| Randall Kaye | Director |
| Lloyd Mackenzie | Executive |
| Krista Mc Kerracher | Director |
| Daniel Mikol | Executive |
| Robert Pilz | Executive |
| Harold Punnett | Director |
| Bill Radvak | Director |
| William Joseph Radvak | Director, Executive |
| Ernest Wong | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
Suite 1703 595 Burrard Street
Vancouver, A1, V7X 1J1
Vancouver, A1, V7X 1J1